NCT00096967

A Study to Evaluate Avastin in Patients Treated in a Previous Genentech-Sponsored Cancer Study

An Open-Label, Multicenter Extension Study of rhuMAb VEGF (Bevacizumab) in Subjects Treated in a Previous Genentech-Sponsored Cancer Study

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 100 (planned)
• Sponsor: Genentech, Inc. · Industry
• Sex: All
• Age: —
• Healthy volunteers: Not accepted

Summary

This is a multicenter, open-label extension study. Subjects who have received rhuMAb VEGF therapy in Study AVF2107g, AVF2119g, or AVF2192g and who completed the parent study are eligible for inclusion in this trial. Subjects who have received placebo in Study AVF2107g or AVF2192g are also eligible.

Conditions

• Breast Cancer
• Colorectal Cancer
• Metastases

Interventions

Type	Name	Description
DRUG	Avastin (bevacizumab)

Timeline

• Start date: 2002-10-01
• Completion: 2004-07-01
• First posted: 2004-11-18
• Last updated: 2014-03-26